Novartis plans to close a Sandoz plant in North Carolina

By:

Published: Sep 9, 2022, 11:53 GMT+00:00

ZURICH (Reuters) - Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on Friday, citing inability to use the U.S. site to full capacity.

ZURICH (Reuters) – Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on Friday, citing inability to use the U.S. site to full capacity.

The site with about 246 employees specialises in producing pharmaceutical oral solid dosage products for distribution mostly in U.S. and Canadian markets.

It said the decision to close the site had come before it announced a strategic review of Sandoz, which it plans to spin off to sharpen the group’s focus on patented prescription medicines.

(Reporting by Michael Shields; Editing by David Goodman)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Did you find this article useful?